Quantcast

Latest Clinical trial Stories

2014-06-04 12:29:56

BETHESDA, Md., June 4, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the Jefferies 2014 Global Healthcare Conference, which is being held in New York. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO NW Bio's presentation will take place on Wednesday, June 4, at 2:00 p.m. EDT in Ballroom 5 at the...

2014-06-04 08:30:44

Raising Expectations of eClinical Solutions CLEVELAND, June 4, 2014 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified eClinical(®) technologies and delivering related services for the clinical trials industry, today announced their engagement at the upcoming DIA Trade Show in San Diego, CA from June 15 -19, 2014. "At DIA 2013, we introduced a transformational upgrade to the DATATRAK ONE(®) platform," said Laurence P. Birch, Chairman...

2014-06-04 08:30:14

SANTA ROSA, Calif., June 4, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, is pleased to announce the distribution of a letter from Hojabr Alimi, the Company's Chairman, Chief Executive Officer and Chief Science Officer, to its stockholders on Form 8-K on June 3, 2014. A download of the full PDF of this...

2014-06-04 04:21:45

VIENNA, June 4, 2014 /PRNewswire/ -- AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients. Upon treatment with AD04, effects consistent with disease modification were achieved for at least 18 months in 47% of treated patients. This beneficial effect was dose dependent and more effective in...

2014-06-03 23:05:52

Third Annual Avoca Quality Consortium Summit Focuses on New Ways to Break Down Silos, Advance Technology, and Build Bridges to Patients during Clinical Trials Princeton, NJ (PRWEB) June 03, 2014 Top executives from across the pharmaceutical and Contract Research Organization (CRO) industries attended the Avoca Quality Consortium Summit on May 6th and 7th to discuss new opportunities for proactively building quality into clinical programs through collaboration. The concept of building...

2014-06-03 08:32:57

GLEN BURNIE, Md., June 3, 2014 /PRNewswire/ -- CSSi, the leader in patient recruitment solutions for the clinical research industry, recently partnered with a major pharmaceutical company to increase the rate of patient screenings and enrollment for an Alzheimer's disease study so that the study would close on time. CSSi was so successful at intervention through its patient enrollment and site performance program that 93% of sites supported by CSSi met or exceeded their goals. In 100%...

2014-06-03 08:32:40

NAPA, Calif., June 3, 2014 /PRNewswire/ -- bioskin(®), a leading dermatology CRO offering global clinical trial services, announces they have joined the Medrio partner program. Using Medrio's eClinical Software as a Service (SaaS) suite, bioskin(®) is able to provide clients a user-friendly, efficient and cost-effective solution for data collection. "Our data managers are able to build the study themselves, without losing valuable time communicating with external programmers....

2014-06-03 08:32:05

SAN DIEGO, June 3, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P(1)) receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics...

2014-06-03 08:31:38

Additionally, Results of Independent Survey Show IV PCA a Burden for Postoperative Care Nurses REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the results of a cost analysis study that showed the use of intravenous patient-controlled analgesia, IV PCA, can...

2014-06-03 08:31:03

Company Announces New Relationship with GlobalCare RESEARCH TRIANGLE PARK, N.C., June 3, 2014 /PRNewswire/ -- Marken announced today that they will host an industry workshop to discuss the emerging direct to patient clinical trial market, and that they have forged a global co-marketing relationship with GlobalCare Clinical Trials, Ltd, the leading global provider of ambulant health care services for clinical trials. http://photos.prnewswire.com/prnvar/20110930/NY78064LOGO Marken's...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related